⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 29, 2025Anticancer Research

Clinical Utility of the Preoperative Cachexia Index in Patients Undergoing Curative Gastrectomy for Gastric Cancer

Junya Morita Takanobu Yamada

View Full Paper

Ask AI

Bookmark

Share

Key Points

Prognostic biomarker may indicate improved survival in gastric cancer patients after surgery.
Findings suggest that preoperative cachexia index (CXI) may be critical for risk assessment post-gastrectomy.
Observational analysis demonstrates the importance of cachexia index in the surgical treatment of gastric cancer.
Potentially informs treatment strategies, enhancing patient management and surgical outcomes.

Implication

Preoperative CXI reveals significant prognostic potential in gastric cancer patients undergoing curative gastrectomy, suggesting improved outcomes.

Abstract

Preoperative CXI may serve as a valuable prognostic biomarker in patients undergoing curative gastrectomy for GC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Morita et al. (2025) studied this question.

synapsesocial.com/papers/6930dc92ea1aef094cca2a11 https://doi.org/10.21873/anticanres.17900

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Low Preoperative Cachexia Index Is Associated with Severe Postoperative Morbidity in Patients Undergoing Gastrectomy for Gastric Cancer2025 · 10 citations
2Preoperative Cachexia Index Predicts Overall Survival Following Curative Resection for Remnant Gastric Cancer.Prognostic Study · 2026
3Impact of the Cachexia Index on survival and recurrence in patients undergoing surgery for gastric cancerReview · 2026
4Clinical significance of the preoperative cachexia index as a prognostic predictor in patients with extrahepatic cholangiocarcinoma undergoing radical surgery.Original Research · 2026
5Prognostic Utility of the Cachexia Index in Resectable and Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant ChemotherapyOriginal Research · 2026